Compare Salesforce Inc (CRM) vs Pfizer Inc (PFE) Price & Performance

Salesforce (CRM) trades at $171.22, up 4.84% today, but remains down significantly year-to-date amid a broader software sell-off. The company demonstrates strong fundamentals with revenue growth to $37.90B in 2025 and a net income margin of 18.73%. Recent quarters show consistent earnings beats, and analyst consensus remains strongly bullish with a $235.90 price target. Technical indicators are mixed, with the stock near key support at $167.

The outlook is positive for long-term investors given robust profitability, AI-driven growth initiatives, and a discounted valuation. Key risks include intense competition in the SaaS sector and macroeconomic sensitivity. The current price presents a potential entry point relative to analyst targets, but volatility may persist in the near term.

Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.

The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.